Karyopharm Therapeutics to merge with Ayrmid as it enters bankruptcy
Karyopharm Therapeutics, a commercial-stage biotech focused on blood cancers, announced it will pursue a merger with Ayrmid while navigating a bankruptcy process. The move aims to combine the two companies' expertise in blood disorders.
Ayrmid, which previously attempted to acquire Bluebird, will become Karyopharm's partner in the restructuring. The merger is intended to preserve ongoing development of Karyopharm's multiple myeloma therapy and other pipeline assets.
The transaction reflects limited options for the cash-strapped biotech and signals a consolidation trend within the blood-cancer sector.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Karyopharm plans to merge with Ayrmid, the company that tried buying bluebird”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that